Total Voting Rights

Summary by AI ^BETAClose X

Aviva plc has announced its total voting rights as of March 31, 2026. The company had 3,050,244,929 ordinary shares issued and admitted to trading, with each share carrying one vote. Following the purchase of 6,720,847 ordinary shares under its share buyback program, which are subject to cancellation, the total number of voting rights in Aviva plc is now 3,043,524,082. This figure will serve as the denominator for shareholders calculating their notification requirements under the FCA's Disclosure and Transparency Rules.

Disclaimer*

Aviva PLC

01 April 2026

Aviva plc

Total Voting Rights

In accordance with the FCA's Disclosure and Transparency Rule 5.6.1, we hereby notify the market of the following:

As at close of business on 31 March 2026, Aviva plc had 3,050,244,929 issued ordinary shares of 32 17/19 pence each (Ordinary Shares) admitted to trading. Each ordinary share carries the right to one vote in relation to all circumstances at general meetings of Aviva plc. Aviva plc does not hold any ordinary shares in treasury.

In addition, on 31 March 2026, Aviva plc had 6,720,847 Ordinary Shares, purchased through the share buyback programme announced on 5 March 2026 and subject to cancellation. Aviva plc does not hold any Ordinary Shares in treasury.

Therefore, as at close of business on 31 March 2026, the total number of voting rights in Aviva plc was 3,043,524,082.

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Aviva plc under the FCA's Disclosure and Transparency Rules.

-ends-

Enquiries:
Media:
Andrew Reid	+44 (0)7800 694 276
Sarah Swailes Alice Constable	+44 (0)7800 694 859 +44 (0)7350 398 942

Analysts:
Michael O'Hara	+44 (0)7387 234 388

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END